PDCD1 and non-small cell lung carcinoma: Anti-PD1/PDL1 monotherapy has become the standard second-line treatment for NSCLC, and a portion of patients achieve long-term survival; nevertheless, the objective response rate (ORR) remains unsatisfactory.